Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 14/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239317 | 0.91 | ALDH1A1 (0.55) | SLC6A7ALDH1A1L3MBTL1TSHRRAB9A | |
| SCHEMBL13316899 | 0.88 | SLC6A7 (0.53) | SLC6A7ALDH1A1L3MBTL1TSHRMEN1 | |
| SCHEMBL13316892 | 0.78 | LMNA (0.61) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3615851 | 0.77 | LMNA (0.51) | RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3603487 | 0.76 | SLC6A7 (0.58) | SLC6A7ALDH1A1L3MBTL1TSHRKDM4E | |
| SCHEMBL5593004 | 0.76 | RAB9A (0.48) | L3MBTL1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8250477 | 0.76 | RAB9A (0.51) | RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5593007 | 0.76 | RAB9A (0.48) | L3MBTL1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8248244 | 0.74 | HDAC6 (0.64) | RAB9A | |
| SCHEMBL13024092 | 0.74 | MEN1 (0.58) | L3MBTL1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | SLC6A7 1931/4885ALDH1A1 370/4885L3MBTL1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.